Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 Study
Author(s) -
Christine MauzKörholz,
Dirk Hasenclever,
W Dörffel,
Kathrin Ruschke,
Tanja Pelz,
Antje Voigt,
Martina Stiefel,
Melanie Winkler,
Constanze Vilser,
Karin Dieckmann,
Jonas Karlén,
Eva Bergsträßer,
Alexander Fosså,
Georg Mann,
Michael Hummel,
Wolfram Klapper,
Harald Stein,
Dirk Vordermark,
Regine Kluge,
Dieter Körholz
Publication year - 2010
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2009.26.9381
Subject(s) - procarbazine , copp , medicine , vincristine , dacarbazine , prednisone , etoposide , lomustine , cyclophosphamide , chemotherapy , gastroenterology , surgery , oncology , heme , biochemistry , chemistry , heme oxygenase , enzyme
Vincristine, etoposide, prednisone, and doxorubicin (OEPA)-cyclophosphamide, vincristine, prednisone, and dacarbazine (COPDAC) is derived from standard vincristine, procarbazine, prednisone, and doxorubicin (OPPA)-cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) chemotherapy by replacing procarbazine with etoposide and dacarbazine for a potentially less gonadotoxic regimen for boys with Hodgkin's lymphoma (HL).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom